Summary of Amylyx Pharmaceuticals Q2 2026 Earnings Call

1Key Financial Results and Metrics

Cash Position: Amylyx ended Q2 2026 with $250.8 million in cash and marketable securities, down from $279.8 million in Q1 2026, providing a runway into 2028.

Operating Expenses: Total operating expenses were $45.7 million, a 7% increase from Q2 2025. R&D expenses decreased to $23.8 million from $27.2 million, while SG&A expenses rose to $21.9 million from $15.6 million, primarily due to legal costs and commercial initiatives.

Stock-Based Compensation: Non-cash stock-based compensation was $8.3 million, up from $7.4 million in Q2 2025.

2Strategic Updates and Business Highlights

Avexitide Development: The pivotal Phase III LUCIDITY trial for avexitide in post-bariatric hypoglycemia (PBH) is on track for top-line data readout expected in late August or early September 2026. The last participant completed their final visit in March.

Regulatory Preparations: The company is preparing for a New Drug Application (NDA) submission, with a focus on NDA readiness and commercial launch preparations for 2027.

Market Engagement: Amylyx launched a disease state education campaign, "Uncover the Mystery of Post-Bariatric Hypoglycemia," to raise awareness among healthcare professionals (HCPs) and patients.

Patient Population: Approximately 160,000 people in the U.S. are estimated to suffer from PBH, with a significant unmet need for treatment.

3Forward Guidance and Outlook

Commercial Launch: If approved, avexitide is expected to launch in 2027. The company is actively building its commercial team and enhancing its market access strategies.

Pipeline Development: The company continues to advance its broader pipeline, including AMX0035 for Wolfram syndrome and AMX0114 for ALS, with ongoing clinical trials and collaborations.

4Bad News, Challenges, or Points of Concern

Increased SG&A Expenses: The rise in SG&A expenses could indicate higher operational costs that may impact profitability.

Regulatory Risks: The company faces uncertainty regarding the potential FDA label for avexitide, particularly whether it will encompass all PBH patients or be limited to those with Roux-en-Y gastric bypass surgery.

Market Competition: While avexitide is positioned as a first-in-class therapy, the competitive landscape remains uncertain, with no other therapies currently approved for PBH.

Placebo Response Uncertainty: There is no historical data on placebo response rates for PBH, which could affect trial outcomes and regulatory approval.

5Notable Q&A Insights

Database Lock and Compliance: The team is focused on data cleaning and ensuring compliance among trial participants before locking the database for the LUCIDITY trial.

Early Access Program (EAP): Interest in the EAP is high, with initial phases open to participants from prior trials.

Patient Population Insights: The company is confident in its prevalence estimates and has identified key centers with a significant number of PBH patients.

ICD-10 Code Impact: The new ICD-10 code for PBH, effective October 1, 2026, is seen as a recognition of the condition, although it is not necessary for reimbursement.

Commercial Strategy: The launch strategy will focus on centers with a high concentration of PBH patients, with plans to expand outreach as awareness grows. Overall, Amylyx Pharmaceuticals is positioned for a significant potential breakthrough with avexitide, pending successful trial outcomes and regulatory approval, while also navigating operational challenges and market dynamics.